Загрузка...
PD-1抑制剂Nivolumab治疗相关的皮肤毒性1例
BACKGROUND AND OBJECTIVE: Nivolumab is an checkpoint inhibitor combining with programmed death-1 (PD-1) receptor on T cells, which can block the interactions between PD-1 and programmed death ligands (PD-L), including PD-L1 and PD-L2. And then block the immunosuppression mediated by the PD-1 pathway...
Сохранить в:
| Опубликовано в: : | Zhongguo Fei Ai Za Zhi |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
中国肺癌杂志编辑部
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6500497/ https://ncbi.nlm.nih.gov/pubmed/31014445 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.09 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|